Drug Trial Radar · NCT02817828
E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia Study
Last checked: Nov 19, 2026Latest source record: Oct 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,577
Actual
Start
Jun 2016
Primary completion
Apr 26, 2018
Study completion Apr 26, 2018
Sponsor
- Lead sponsor
- EstetraIndustry
- Sponsor type
- Industry
- Collaborators
- PRA Health Sciences
- First posted
- Jun 29, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objectives of this study are to evaluate the contraceptive efficacy, vaginal bleeding pattern (cycle control), and the general safety and acceptability of the 15 mg estetrol (E4)/3 mg drospirenone (DRSP) combination in healthy women aged 18 to 50 years.
Conditions
- Contraception
Interventions
15 mg E4/3 mg DRSPDrug
15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in Subjects Aged 18 to 35 Years, Inclusive, at the Time of ScreeningTime frame: Up to 12 months (13 cycles with 1 cycle = 28 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hopital Saint-Pierre
Brussels, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.